GlassScriptPhysician profile
Soloman Shah
NPI 1578524997
$7,088.60
in general payments reported to CMS, 2019-2025
31 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $551 · 2021: $1,271 · 2022: $1,399 · 2023: $292 · 2024: $1,496 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,344.11 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,719.25 | 2019-2025 | Creon, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,167.01 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $714.27 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $524.48 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $421.26 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $315.60 | 2024-2025 | Voquezna |
| Celgene Corporation | $302.16 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $224.06 | 2022-2025 | Dupixent |
| Genzyme Corporation | $184.66 | 2022-2025 | |
| Boston Scientific Corporation | $158.03 | 2022-2025 | General - Metal Stents - G.I. |
| Ferring Pharmaceuticals INC. | $146.02 | 2019-2023 | Rebyota |
| Ardelyx, INC. | $138.20 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $120.62 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $112.82 | 2020-2022 | |
| Pfizer INC. | $98.31 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $90.88 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $69.73 | 2020-2024 | |
| Alfasigma USA, INC. | $67.20 | 2020 | |
| Nestle Healthcare Nutrition INC. | $66.20 | 2021-2023 | |
| Ambu INC. | $62.07 | 2022 | |
| Daiichi Sankyo INC. | $60.56 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $59.77 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $50.46 | 2024-2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $50.14 | 2024-2025 | Givlaari |
| Braintree Laboratories, INC. | $34.70 | 2020-2021 | |
| Evoke Pharma, INC. | $28.88 | 2024-2025 | |
| Endogastric Solutions, INC | $27.01 | 2019 | |
| W. L. Gore & Associates, INC. | $19.88 | 2022 | |
| Medtronic, INC. | $19.08 | 2025 | Synchromedii |
| Shionogi INC | $18.06 | 2019 | |
| Merck Sharp & Dohme LLC | $17.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soloman Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.